Antimicrobials | CMAC

Antimicrobials

Safety of Monofluoroquinolones in Pediatric Patients

Two groups of children on therapy with monofluoroquinolones were enrolled in this open trial: 169 patients with cystic fibrosis (exacerbation period) and 55 patients with aplastic anemia (neutropenic phase); age was from 6 months to 16 years. The aim …

New oral formulation for the Treatment of Community-Acquired Lower Respiratory Tract Infections

Azithromycin is one of the most commonly used macrolides in the treatment of respiratory tract infections. Azithromycin is a popular antimicrobial due to a number of its unique pharmacokinetic and pharmacodynamic properties. This review describes the …

Use of Carbapenems in Clinical Practice: When, Which and How Long?

Carpabenems (imipenem, meropenem, ertapenem) are currently one of the antibiotic classes that exhibit the broadest spectrum of activity and characterized by the low resistance rates of clinically significant pathogens. This article is an attempt to …

Clinical and Pharmacoeconomic Analysis of the Fluconazole Use for the Prophylaxis of Invasive Candidiasis in Very-Low-Birth Weight Infants

Very-low-birth weight preterm infants (<1500 g) are at high risk for invasive candidiasis. The prospective randomized controlled clinical trial comparing efficacy of 2 doses of fluconazole (3 and 6 mg/kg) in the prophylaxis of invasive candidiasis …

Gemifloxacin in the Treatment of Community-Acquired Lower Respiratory Tract Infections

Gemifloxacin is a new respiratory fluoroquinolone that was approved as Factive® in Russian Federation in December 2005. Among the fluoroquinolones this agent is the most active against Streptococcus pneumoniae, and has similar to other respiratory …

Comparative Pharmacodynamics of Daptomycin and Vancomycin with Staphylococcus aureus in an in vitro Dynamic Model

To compare the pharmacodynamics of daptomycin (DAP) and vancomycin (VAN) as well as killing kinetics of S. aureus with different MICs were studied at widely ranged AUC/MIC ratios. Two clinical isolates, S. aureus 866 (MICDAP 0.35 µ/ml and MICVAN 0.70 …

Amoxicillin/Sulbactam – a New Beta-Lactam/Beta-Lactamase Inhibitor Combination

Beta-lactams are the most commonly used class of antimicrobial agents for the treatment of community-acquired and nosocomial infections. One of the resistance mechanisms for this class is a production of beta-lactamases. To overcome this problem, the …

Potential for the Use of Probiotics in Clinical Medicine

Currently, prophylactic and therapeutic use of probiotics is a common practice worldwide, although their effectiveness remains controversial. This review presents data on main probiotic microorganisms. This paper summarizes available evidence-based …

Azithromycin: Current Clinical Use

Discovery and introduction into the clinical practice of macrolide antibiotics is one of the major advances in the history of antimicrobial therapy. The most prescribed macrolide is azithromycin, which is due to a number of its unique pharmacokinetic …

β-Lactam/β-Lactamase Inhibitor Combinations: Role in the Antimicrobial Therapy

At present, β-lactams are the most commonly used antimicrobials, but their clinical efficacy may be reduced because of the spread of antimicrobial resistance. The most important mechanism of resistance to β-lactams is an inhibition by the microbial …